Summary · why it matters
Ruanyun Edai Technology Inc., trading as RYET, has signed a definitive agreement to grant BioNexus Gene Lab Corp., or BGLC, an exclusive license to its Cogni AI document-intelligence platform for healthcare in Malaysia, alongside a reciprocal share exchange. The license runs ten years from closing and is renewable at BGLC's option for two further five-year terms, up to 20 years in total, and is exclusive in Malaysian healthcare for the full term. RYET would receive a 10% royalty on qualifying technology receipts collected by BGLC and its affiliates, with no minimum royalty or guaranteed revenue, and the same 10% royalty applies to any other industry BGLC adds in Malaysia by notice. At closing BGLC would issue 410,000 common shares to RYET for the license, a consideration of US$3.5 million, and a further 150,000 shares in exchange for 500,000 new RYET ordinary shares, with no cash payment or true-up. Based on Nasdaq closing prices on October 2, 2026, of US$1.27 for BGLC and US$0.8599 for RYET, the 410,000 license shares had a quoted value of US$520,700, the 150,000 BGLC exchange shares US$190,500, and the 500,000 RYET shares US$429,950. The deal comes as Malaysia accelerates public healthcare digitalization, after Prime Minister Anwar Ibrahim announced a RM1 billion allocation on August 30, 2026, involving 150 hospitals and 2,000 health clinics, though neither company is a party to or has been awarded any contract under these government programs, and Cogni AI is not an electronic medical records system. Closing remains subject to conditions including BGLC's written acceptance of the technology after testing, due diligence, corporate and regulatory approvals, and any PRC approval, registration or license RYET needs to license and deliver the technology, with either party not in default able to terminate if closing has not occurred by March 31, 2027.
BioNexus Gene Lab Corp Common stock
Ruanyun Edai Technology Inc. Ordinary shares
OK Rusal MKPAO